Like Taylor Swift's brother, the BMW 2 Series Gran Coupé knows a thing or two about being overshadowed by a sibling. For while it's closely related to the 1 Series, that family hatchback gets ...

A new Batman #1 is coming this September with a throwback blue and gray costume, a new Batmobile, and "all the stuff that makes Batman the coolest character in comics." Fraction and Jiménez are ...

CSL (ASX:CSL) has posted its half-year results, delivering results that are best described as mixed. At the headline level, revenue climbed around five per cent, while net profit after tax and ...

Last November, I strapped into the rear passenger seat of an all-electric, four-door sedan with BMW test driver and 24-hour racer Jens Klingmann behind the wheel. It was a cold day at BMW’s ...

The BMW Vision Driving Experience may not have a particularly exciting name, but what that moniker disguises is the car's purpose: it's a test bed for BMW to show off its latest and greatest ...

Yes. Yes it is. Honestly, Spin Master might have knocked it out of the park with their Batman Forever Retro Batmobile, in more ways than one. On the surface, it’s screen accurate, looking like ...

ASX health stocks fell 3.78% over the past week, while the broader market edged up 0.77% Australia’s biggest health care name CSL weighed on sector with soft H1 FY25 result Shares of merged Chemist ...

The CSL Ltd (ASX: CSL) share price hit a 52-week low of $253.95 on Wednesday. Since the end of July 2024, it has dropped close to 20%. Investors may be asking themselves whether this ASX blue-chip ...

Developed by Australia’s CSL Limited (ASX: CSL) and to be marketed by its CSL Behring unit, Andembry inhibits plasma protein factor XIIa, which initiates the cascade of events leading to angioedema at ...

ANDEMBRY reinforces CSL's decades-long commitment to delivering innovative treatment modalities to the HAE community and comes with a convenient patient-centric pre-filled pen (auto-injector) enabling ...

“ANDEMBRY, CSL’s first approved recombinant monoclonal antibody discovered and developed entirely by CSL, underscores our more than 40-year legacy in HAE research and treatment optimization and our ...

For the six months to 31 December, CSL reported a 5% rise in revenues (on a constant currency basis) to US$8.48 billion. Net profits after tax were up 7% to US$2.04 billion. Even so, investors ...